ORIC-101

Data and regulatory roundup: Pfizer’s feat, an ADHD miss, Eli Lilly’s CRL & more
MedCity News
Mon, 03/28/22 - 10:17 am
FDA
Pfizer
etrasimod
Argenxy
efgartigimod
Aligos Therapeutics
Vallon Pharmaceuticals
Adderall
ORIC Pharmaceuticals
ORIC-101
Neurana Pharmaceuticals
tolperisone
Eli Lilly
sintilimab
ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers
Xconomy
Mon, 03/2/20 - 11:14 pm
ORIC Pharmaceuticals
IPOs
cancer
ORIC-101